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This paper examines the value relevance of R&D reporting among public listed 
companies in Malaysia for the years 2000 and 2001, subsequent to the introduction of 
FRS 109, Accounting for Research and Development (formerly known as MASB 4). FRS 
109 states that a firm should expense its research costs and could capitalize the 
development cost if the latter is expected to bring future benefits. Otherwise, the 
development expenditure is to be expensed. Test results based on Ohlson's (1995) 
valuation model shows that for capitalizers, the amount of R&D expenditure, either 
expensed or capitalized, influences the stock prices positively. As for the expensers, even 
though the amount expensed influences stock prices, this relationship is driven by outliers; 
when we dropped the outliers, the result is no longer significant. These results indicate 
that R&D activities of capitalizers are expected to bring future benefits and consequently 
lead to higher prices while the R&D activities of expensers are more difficult to evaluate 
given a small sample size and the presence of outliers. 
* Lecturer at the Faculty of Finance and Banking, Universiti Utara Malaysia ** Lecturers at the Faculty of Accountancy, Universiti Utara Malaysia 
I. INTRODUCTION 
Rapid technological changes and the growth of science and knowledge-based industries 
have become the norm of modem corporations. To compete in today's global market, a 
company must not only keep abreast of the current changes but more importantly be the 
pioneer of technological breakthrough. This necessitates a company to take on research 
and development (R&D) activities. 
Generally, R&D activities require a company to invest a certain amount of capital in 
which the outcome of that investment is uncertain. Companies expect that the investment 
would yield a positive net present value, i.e. would create value to the companies. The 
evidence from the capital markets seems to support the argument that R&D is a positive 
net present value investment. Chan, Martin and Kensinger (1990) for instance look at the 
abnormal returns of 95 firms that announced that they would increase their R&D 
spending. They find that investors reacted positively to the announcement of R&D 
expenditures with the two-day announcement return of 1.38%, which is statistically 
significant. Furthermore, they find that the positive return is driven by firms in the high- 
technology industries. The two-day return of 2.1% of firms in the high-technology sector 
is significant while the corresponding figure for the low-technology sector of -0.9% is 
also significant. Therefore, even though R&D could bring benefits to firms, these benefits 
accrue mainly to the high-technology industries. 
As far as the accounting for R&D is concerned, traditionally there have been two 
approaches in treating the cost of R&D activities. The R&D cost could be recognized 
either as an expense or as an asset and then amortized over the period benefited. The 
debate over whether R&D spending should be expensed or capitalized has been ongoing 
for a long time. In the US, the accounting treatment of R&D is hotly debated since firms, 
except for those in the software industry, are required to expense their R&D spending. 
Regulators prefer to expense R&D since it is implicitly assumed that expensing rather 
than capitalizing R&D outlays increases the objectivity of financial statements. Given the 
outcome of many of these R&D outlays is uncertain and unreliably measured, objectivity 
has been the primary justification for the prescribed standards internationally. On the 
other hand, researchers (see for e.g. Lev, 1999; Chan, Lakanishok and Sougiannis, 2001) 
argue that the failure to recognize R&D as an asset will seriously distort common 
accounting measures such as price-earnings ratio, market to book ratio, and leverage ratio. 
Companies with high R&D spending would therefore appear to be highly leveraged and 
highly priced as compared to companies that do not have R&D spending. This will not 
only impair the credibility and relevance of financial reporting but also hinder firms' 
growth potential and value. 
In Malaysia, the accounting treatment for R&D depends on the expectation about the 
future benefits of an investment in R&D. If the investment is not expected to lead to 
future benefits, then the company has to treat the investment as an expense. However, if 
the investment is predicted to bring future benefits, then the investment cost is allowed to 
be capitalized. Based on the current accounting standards, in Malaysia as well as overseas 
(for example Australia, Singapore, Korea and the UK) only eligible development costs 
can be capitalized and amortized. Whereas all costs related to research activities are 
expensed immediately. 
A review of literature shows that numerous studies have been conducted in the US and 
some other jurisdictions (Australia, Japan and Korea for example) to examine the effect 
of R&D spending on firms' value. However, no such studies have been undertaken in 
Malaysia, and to fill the missing gap it is felt necessary that this study be conducted. As 
the Malaysian accounting standard, unlike that of the US, allows expensing and 
capitalization of R&D expenditure (subject to certain criteria) this study makes an 
interesting and significant contribution to the accounting body of knowledge. 
Generally, the objective of this study is to investigate the impact of R&D spending on 
firms' market value. In addition, it attempts to demonstrate whether the stock market 
appropriately incorporate the value of long-term benefits of R&D spending. The findings 
can alert standard setters of the implication of FRS 109', Research and Development 
Costs, which to some extent limits management discretion as to when R&D spending can 
be capitalized. Finally it is hoped that the evidence on the value relevance of R&D 
spending can promote companies to undertake R&D activities as their future economic 
benefits will be shared by consumers, the firm, and the nation as a whole. 
The rest of this paper is organized as follows. The next section discusses the accounting 
standard of R&D in Malaysia and reviews previous studies on value relevance of R&D 
spending. Following that, there is a section on research methods, in which data collection 
and relevant valuation models are discussed. Results and discussions are presented next, 
following which this paper concludes the study. 
11. LITERATCsRE REVIEW 
Accounting Standard for R&D in Malaysia 
The accounting standard for R&D in Malaysia is prescribed by FRS 109. The standard 
defines research as an original and planned investigation undertaken with the prospect of 
gaining new scientific or technical knowledge and understanding. While development is 
the application of research findings or other knowledge to a plan or design for production 
of new or substantially improved materials, devices, products, processes systems, or 
services prior to the commencement of commercial production or use. 
FRS 109 prescribes that all research costs be expensed in the period incurred (paragraph 
15) and developments cost of a project be recognized as an asset and be amortized over a 
period not exceeding five years (paragraph 23) if a project meets all of these criteria: 
' Known as MASB 4 prior to 1 January 2005. 
a. The product or process is clearly defined and the costs attributable to the 
product or process can be separately identified and measured reliably; 
b. The technical feasibility of the product or process can be demonstrated; 
c. The enterprise intends to produce and market, or use, the product or process; 
d. The existence of market for the product or process or, if it is to be used 
internally rather than sold, its usefulness to the enterprise, can be 
demonstrated; and 
e. Adequate resources exist, or their availability can be demonstrated to 
complete the project and market or use the product or process. 
FRS 109, in tandem with International Accounting Standards No. 9 (revised), requires 
the exercises of prudence judgment in determining the economic viability and certainty of 
development costs to be recognized as an asset. 
Prior Studies 
Most of the studies on R&D have been canied out in the US. Compared to FRS 109, the 
US Statement on Financial Accounting Standards No. 2 (1974) prescribes a more 
stringent rule for costs associated with R&D. The latter states that direct relationship 
between R&D costs and specific future benefits as measured by subsequent sales, 
earnings, or market share of industries does not exist. Therefore, all research costs should 
be expensed when incurred. Managers burdened to achieve short-term profit target will 
find R&D spending as possible target of cuts. In 1985, the US Financial Accounting 
Standards Board (FASB) made an exception to full expensing requirement for some 
software development costs. This is because the investment on software development has 
demonstrated to produce future economic benefits. 
Since the benefits of R&D are difficult to assess, regulators in the US try to prevent the 
opportunistic behavior of managers by requiring firms to expense their R&D expenditure. 
Given the pros and cons of both expensing and capitalizing R&D activities, standard 
setters around the world have to a make a choice between the two opposing forces. One is 
the potential abuse that could arise if a firm is allowed to choose between expensing and 
capitalizing and the other is the distortion in the financial statements if a firm has to 
expense its R&D expenditure. 
Lev (1999) has been critical of the way that R&D is accounted for in the US. He argues 
that full expensing of R&D spending is distorting the true financial picture of a firm. Lev 
and Sougiannis (1996) look at the effects of R&D on stock returns and prices. In testing 
the relevance of R&D expenditures, they measure the benefits of the expenditures on 
current and future earnings. They find that the effects of R&D on earnings range from 
five years (for firms in the scientific instruments industry) to nine years (for firms in the 
chemicals and pharmaceutical industry). Furthermore, they find that the understatements 
of earnings and equity are 20.55% and 22.2%, respectively. The effect of R&D on return 
on equity (ROE) is ambiguous; ROE is understated for firms that experienced high 
growth rates of R&D and overstated for firms with low growth rates. Finally, they find 
that the difference between restated earnings (assuming capitalization), and reported 
earnings is positively related to both price and stock returns, and the difference between 
restated book value of equity and reported book value of equity is positively related to 
price. Therefore, they conclude "R&D capitalization yields statistically and significantly 
reliable and economically relevant information" (p. 134). 
Aboody and Lev (1998) examine firms in the software industry where capitalization of 
R&D costs is allowed. They find that the stock price is positively related to the book 
value of capitalized software asset, changes in earnings one-year and two-year ahead are 
positively related to changes in the capitalized amount of software development, and 
changes in the capitalized amount of software development could explain 
contemporaneous stock returns. Therefore, capitalization of R&D costs provides useful 
information to investors. As for the firms that fully expensed their R&D costs, they find 
that even though the amount expensed could not explain contemporaneous stock returns, 
the amount expensed could explain returns one-year or two-year ahead. 
Chan et al. (2001) studied the impact of R&D intensity, i.e., R&D expenditures scaled 
either by sales or by market value of equity, on returns. They find that returns of firms 
that carried out R&D activities do not differ from those of firms that do not cany out the 
activities irrespective of the level of R&D intensity when the intensity is measured 
relative to sales. However, when R&D intensity is measured relative to the market value, 
they find that firms with the highest R&D intensity outperform their controls. Further 
investigation suggests that R&D intensity is strongly related to stock volatility. They 
suggest that the lack of accounting disclosure might help explain this volatility. However, 
Aboody and Lev (1998), in investigating the reason behind financial analysts' calls to 
abolish Statement on Financial Accounting Standards No. 86, find that analysts have 
trouble in forecasting earnings of firms in the software industry. They find that the higher 
the annual R&D costs relative to market value, the greater the forecast error is. 
Zhao (2002) compares the accounting standards on R&D among four countries: the US, 
the UK, France, and Germany. Germany and the US require full expensing of R&D 
expenditures while France and the UK allow firms to capitalize the expenditures. They 
find that for the sub-sample of capitalizing firms, both the periodic expenditures and the 
book value of capitalized R&D costs could explain the stock prices. Therefore, 
capitalization provides meaningful information to investors. 
Abrahams and Sidhu (1998) look at the effects of R&D on firm value in Australia. In 
Australia, a firm is allowed to capitalize its R&D spending if certain requirements are 
met. They find that the stock prices are positively related to the capitalized R&D costs. 
Furthermore, reported earnings, net of expenses and amortizations associated with R&D, 
are better able to explain share price than earnings before taking into account the 
expenses and amortizations. Therefore, in Australia the benefits of sharing the 
information through capitalization outweigh the potential abuse of spicing up the 
financial statements. 
Xu and Zhang (2004) look at the role of R&D in explaining returns in Japan and they 
find that R&D is useful in explaining returns in the post-bubble period, i.e., from 1993 to 
2000. Furthermore, they find that R&D leads to higher volatility in the post-bubble 
period but not for the whole sample period. Han and Manry (2004) investigate whether 
R&D influences stock prices in Korea, in which capitalization of R&D expenditures is 
allowed. They find that for firms that choose to capitalize, the book value of the 
capitalized asset is strongly associated with stock prices and for firms that choose to 
expense, the expensed amount is positively related to the prices. 
As a summary, the international evidence points toward the relevance of R&D 
capitalization in the financial reports. Capitalization of R&D expenditure might provide 
additional information that users of financial statements could use in evaluating a firm. 
111. RESEARCH METHODS 
Data 
FRS 109 specifically defines development expenditures as the application of research 
findings in which this research should be original and planned investigation to gain new 
scientific or technical knowledge and understanding. Based on casual inspection of 
annual reports of companies listed on Bursa ~ a l a ~ s i a ~ ,  "development expenditure" also 
applies, among others, to plantation development, forestry development, property 
development, and courses and syllabi development expenditures. Therefore, this study 
excludes companies involved in plantation, property and real estate, construction, and 
education, as their development expenditures are not R&D per se as defined under FRS 
109. 
Furthermore, diversified companies usually lumped together the amount spent on 
development expenditures, making it difficult to disaggregate the spending directly 
related to R&D as defined in FRS 109. As most firms in the trading and services industry 
are highly diversified, they are also excluded in this study. Firms in the financial industry 
are also excluded because of their unique regulatory environment. 
Our final sample consists of 126 Bursa Malaysia Main Board companies in three major 
industries, i.e., industrial products, consumer products and technology. Annual reports for 
the years 2000 and 2001 are examined. Due to unavailability of six annual reports, our 
Formerly known as the Kuala Lumpur Stock Exchange (KLSE). 
final sample consists of 246 firm-years. Out of these, 76 firm years are capitalizers, 23 
are expensers, and 147 do not carry out any R&D activities. In addition, companies' 
annual reports for the years 2000 and 2001 are observed for other relevant information. 
We also use Datastream database to extract data related to stock prices. 
Regression Models 
Ohlson (1995) shows the relationship between book value of equity and earnings to share 
price. He posits that prices could be explained by book value of equity, earnings, and 
other information. Based on Ohlson (1995), the relationship is estimated using the 
following model: 
Pit = 1IDL7 lYearit + U2EPSit + II3BVit + eit (Model 1) 
where: 
pit = stock price for firm i at the end of year t. 
Yearit = year dummy for firm i (one for year 2001 and zero for year 2000) 
EPSit = earnings per share for firm i in year t. 
BVit = book value of equity per share for firm i in year t. 
To test the relationship between R&D and share prices, the above model is expanded by 
including the R&D variable as follows: 
Pit = ODU 1Yearit + f12EPSit + q 3BVit + 0 4R&Dpershareit + eit (Model 2) 
where R&Dpershareit = Total R&D expenditure per share for firm i in year t, and other 
variables as previously defined. 
The EPS and BV in Model 2 are further broken down as follows. EPS is broken into two 
components: EPS before taking into account the expensed R&D, and the expensed R&D 
per share. Furthermore, since some of the capitalizers expensed some portion of their 
R&D expenditures, the expensed R&D per share is further broken down into two 
components. One is the expense by the expensers and the other is the expense by the 
capitalizers. Therefore, 
EPSit = EPSbefit - (ExpFullit + ExpCapit + AmortCapit + Writeoffit) where 
EPSbefi, = EPS before taking into account the expensed R&D. 
ExpFullit = expensed R&D per share by the expensers. 
ExpCapit = expensed R&D per share by the capitalizers. 
AmortCapit = amount of amortization per share by the capitalizers. 
Writeoffit = amount of write-off per share by the capitalizers. 
Similarly, BV is broken down into two components, i.e., the BV before taking into 
account the capitalized amount, and the capitalized amount of R&D per share. Therefore, 
BVit = BVbefit + CapAmtit where 
BVbefit = BV per share before taking into account the capitalized amount of R&D. 
CapAmtit = capitalized amount of R&D per share. 
Thus, the final model that we estimated takes the following form: 
Pit = O D 0  ,Yearit + 02EPSbegt + q 3E~pF~l l i t  + 04ExpCapit + q sBVbefit 
+ q 6CapAmtit + eit, (Model 3) 
where the variables are as defined previously3. 
We expect that O2  is greater than one since the prices should capitalize the information 
inherent in EPS. As for 03,  the sign is not clear. If investors believe that the expenses are 
not going to affect profitability, then the coefficient should not be different from zero. 
However, the opponents of the expensed method argue that R&D is going to affect a 
firm's profitability and thus, we should expect the coefficient to be greater than one. The 
sign of U 4  is not clear. The argument is similar to 03. As for 05,  the coefficient should be 
greater than zero. Finally, if R&D is important and contribute to the future survival of the 
firm, we expect that q 6 should be greater than one. 
IV. RESULTS AND ANALYSIS 
Table 1 provides the descriptive statistics. There are 23 expensers, 76 capitalizers, and 
147 observations that do not spend any money on R&D, subsequently referred to as non- 
R&D. Comparing the three groups, we find that the share prices of expensers and 
capitalizers are higher than those of the non-R&D and these differences are significant at 
the 10% and 5% level respectively. However, the share prices of the expensers are not 
statistically different from the share price of the capitalizers. EPS, BV, EPSbef, and 
BVbef of the expensers are significantly greater than those of the non-R&D and the 
capitalizers while the averages for the non-R&D are greater than those of the capitalizers. 
R&D expenditure, which is equal to the amount expensed plus the amount capitalized, 
and R&D expenditure per share are also statistically different between capitalizers and 
expensers. However, these differences are driven by four firms, with eight firm-years 
data. When these eight observations are dropped, the differences are no longer significant. 
Finally, expensers are larger than both capitalizers and firms with no R&D while the size 
of capitalizers are not statistically different form the size of firms with no R&D 
investments. 
(INSERT TABLE 1 HERE) 
Table 2 reports the correlations between the variables of interest. As expected, the 
correlation between EPS and EPSbef of 0.9926 and BV and BVbef of 0.9999 are high4. 
The correlation between EPSbef and BVbef is 0.605. Even though this figure is high, it is 
- - - 
3 We do not include the results of AmortCapi, and Writeoffit since we are not interested in these coefficients. 
However, this is not a cause for concern as the variables are not going to be used simultaneously. 
not a cause of concern. We check for the existence of multicollinearity in our model by 
looking at variance inflation factors and none of the models suffers from the existence of 
multicollinearity problems. 
(INSERT TABLE 2 HERE) 
Table 3 shows the results of the regression model. The first model, on the second column, 
shows that only EPS affects the value of a firm. The coefficient for EPS is a statistically 
significant 2.564, which means that a one cent change in EPS leads to a price change of 
2.564 cents. The coefficient on BV of 0.139 is not statistically significant even though the 
value is between zero and one. The adjusted R~ of 0.201 is low but it is consistent with 
the findings of Graham and King (2000). Graham and King (2000) find that the adjusted 
R~ of the Ohlson's model in Malaysia is 0.277, which is the second lowest among the six 
Asian countries that they survey in their paper. However, they find that the coefficient on 
BV is statistically significant. The different in results between this paper and theirs might 
be due to the different sample period. Their sample period from 1987 to 1996 reflects the 
economy expansion period while this paper uses 2000 and 2001, a period of lower 
economic expectations in Malaysia. 
(INSERT TABLE 3 HERE) 
The third column of Table 3 presents the findings of the second model, that is, when the 
variable R&Dpershare is added to the first model. The coefficient of R&Dpershare is a 
statistically significant 15.309. This coefficient is also economically significant as a one 
standard deviation change in R&Dpershare would lead to a 79 cents change in price. The 
coefficients of EPS and BV are statistically significant even though not significant as in 
the first model. The adjusted R~ increases from 0.201 to 0.3 19. 
The fourth column summarizes the results associated with the final model. Using this 
model, we find that the statistical significance of EPSbef and BVbef are similar to the 
previous models, i.e., EPSbef is significant while BVbef is not. The coefficient for 
ExpFull, which represents f m s  that fully expensed their R&D expenditures, is 
significant and the sign is as predicted, i.e., positive and greater than one. A one standard 
deviation change in this coefficient leads to a 46 cents change in price. Firms are not 
going to spend on R&D if they believe that their spending would not lead to future 
benefits. Therefore, even though the expensers fully expensed their R&D costs, investors 
expect that the investment in R&D by these firms would lead to future benefits and thus, 
they impounded these benefits into current stock prices. This finding differs from the 
finding of Aboody and Lev (1998). Aboody and Lev (1998) find that for the software 
companies that choose to fully expensed their R&D spending, the expenses do not affect 
current period returns but future returns. Han and Manry (2004) find that fully-expensed 
firms have higher prices, which is consistent with our results. 
The coefficient of ExpCap is 141.643 and is statistically significant. Since a one standard 
deviation change in ExpCap leads to a 31 cents change in prices, this coefficient is also 
economically significant. An explanation of this result is that, even though the 
capitalizers expensed some of their R&D spending, the effects of the spending would still 
be felt in the future. Therefore, the prices reflect this information. However, the result of 
this variable should be interpreted cautiously since we only have six observations. When 
we throw out these observations, the results of other coefficients do not change in sign or 
significance. 
Finally, the coefficient for CapAmt is a statistically significant 22.974. CapAmt is also 
economically significant as a one standard deviation change in this variable leads to a 56 
cents change in price. The significant and positive effects of CapAmt on prices show that 
the capitalization of the R&D activity leads to future economic benefits and these 
benefits are impounded into the prices. The result of this coefficient is consistent with the 
results of Aboody and Lev (1998) and Man and Hanry (2004). 
The results in Table 3 are not clean of outliers. Among the expensers, we find that there 
are eight observations with R&D spending of at least RM46 million5. When we exclude 
these eight observations from the sample, the average R&D expensed for the remaining 
15 observations dropped from RM23.4 million (when 23 firm-years were observed) to 
RM1.5 million. Table 4 shows the results when we exclude the outliers from our sample. 
(IIVSERT TABLE 4 HERE) 
The models in Table 4 have lower adjusted R~ compared to the models in Table 3 when 
all firms are used. Furthermore, when we exclude the outliers, we find that the coefficient 
of firms that fully expensed their R&D expenditures is not significant anymore while the 
rest of the coefficients maintain their significant level. Therefore, the presence of outliers 
influences our earlier results for ExpFull. However, we have to be cautious in interpreting 
this result since the sample size is very small. 
In summary, our results show that for both expensers and capitalizers, the amount of 
R&D expenditure lead to future economic benefits and these benefits are reflected in the 
stock prices. These results are consistent with the findings of Aboody and Lev (1 998) and 
Han and Manry (2004). However, for expensers, the result is influenced by the existence 
of outliers. 
IV. CONCLUSION 
This study investigates whether accounting method for R&D affects the stock prices. 
Firms are allowed to capitalize their R&D spending if certain criteria are met. We find 
that for capitalizers, the amount of R&D either expensed or capitalized influence the 
RM being Ringgit Malaysia, which is the Malaysian currency. 
stock prices positively. As for the expensers, even though the amount expensed influence 
the stock prices but this relationship is driven by outliers; when we dropped the outliers, 
the result is no more significant. These results indicate that R&D activities of capitalizers 
are expected to bring future benefits and consequently lead to higher prices while the 
R&D activities of expensers are more difficult to evaluate given a small sample size and 
the presence of outliers. 
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Table 1: Descriptive statistics (all figures in RM except for R&DperSales): 
Mean (standard deviation) of variables 
a, b, c, and nsl refer to the difference between expensers and capitalizers for a variable of 
interest being significant at 1%, 5%, lo%, and not significant respectively. 
d, e, f, and irr2 refer to the difference between expensers and no-R&D for a variable of 
interest being significant at 1 %, 5%, lo%, and irrelevant respectively. 
g, h, i, and ns3 refer to the difference between capitalizers and no-R&D for a variable of 
interest being significant at 1 %, 5%, 10% and not significant respectively. 
Price: Adjusted price at financial year end 
Sales: Sales 
EPS: Earnings per share 
BV: Book value per share 
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ExpR&D (in RM): The amount of R&D being expensed 
ExpR&Dper share: The amount of R&D being expensed divided by total shares 
outstanding 
BVbef : Book value per share before taking into account the capitalized amount per share 
CapAmt (in RM): Amount of R&D being capitalized 
CapAmtpershare: Amount of R&D being capitalized divided by total shares outstanding 
R&D Expenditures: Total R&D expenditures each year 
R&DperSales: The ratio of total R&D expenditures to the total sales 
R&Dpershare: Total R&D expenditures each year divided by total shares outstanding 
Table 2: Correlations among variables 
I Sales L 
***, **, and * signify that the correlations are significant at 1%, 5%, and lo%, 
respectively 
Price: Adjusted price at financial year end 
EPS: Earnings per share 
BV: Book value per share 
EPSbef : Earnings per share before taking into account the expenses amount per share 
BVbef : Book value per share before taking into account the capitalized amount per share 
ExpFull: The amount of R&D per share being expensed by the expensers 
CapAmt: Amount of R&D being capitalized divided by total shares outstanding 
ExpCap: The amount of R&D per share being expensed by the capitalizers 
R&Dpershare: Total R&D expenditures each year divided by total shares outstanding 
Sales: Sales 
Table 3: Results of the models for the full sample 
EPS: Earnings per share 
BV: Book value per share 
EPSbef : Earnings per share before taking into account the expenses amount per 
share 
ExpFull: The amount of R&D per share being expensed by the expensers 
ExpCap: The amount of R&D per share being expensed by the capitalizers 
BVbef : Book value per share before taking into account the capitalized amount 
per share 
CapAmt: Amount of R&D being capitalized divided by total shares outstanding 

















Table 4: Results of the models when eight firm-years are taken out 






EPS: Earnings per share 
BV: Book value per share 
EPSbef : Earnings per share before taking into account the expenses amount per 
share 
ExpFull: The amount of R&D per share being expensed by the expensers 
ExpCap: The amount of R&D per share being expensed by the capitalizers 
BVbef : Book value per share before taking into account the capitalized amount per 
share 
CapAmt: Amount of R&D being capitalized divided by total shares outstanding 
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